Frontiers

Frontiers of Digital Finance by Biz2X Named as Fintech Ecosystem Partner for the Dubai FinTech Summit 2024 on May 8

Retrieved on: 
Wednesday, March 27, 2024

DUBAI, United Arab Emirates, March 27, 2024 (GLOBE NEWSWIRE) -- Biz2X and Dubai International Financial Centre ( DIFC ) today announced that Frontiers of Digital Finance (FDF) will be an official event at the 2024 Dubai FinTech Summit.

Key Points: 
  • DUBAI, United Arab Emirates, March 27, 2024 (GLOBE NEWSWIRE) -- Biz2X and Dubai International Financial Centre ( DIFC ) today announced that Frontiers of Digital Finance (FDF) will be an official event at the 2024 Dubai FinTech Summit.
  • FDF Dubai will feature key industry leaders from financial institutions, technology platforms, global consultancies, and government officials in an invite-only event on May 8, 2024.
  • In collaboration with DIFC Innovation Hub, the event will also spotlight Dubai's groundbreaking Vision D33 for transforming finance in the Emirates.
  • We are proud to be hosting these urgent and powerful conversations with the Frontiers of Digital Finance series."

Frontiers of Digital Finance by Biz2X Named as Fintech Ecosystem Partner for the Dubai FinTech Summit 2024 on May 8

Retrieved on: 
Wednesday, March 27, 2024

DUBAI, United Arab Emirates, March 27, 2024 (GLOBE NEWSWIRE) -- Biz2X and Dubai International Financial Centre ( DIFC ) today announced that Frontiers of Digital Finance (FDF) will be an official event at the 2024 Dubai FinTech Summit.

Key Points: 
  • DUBAI, United Arab Emirates, March 27, 2024 (GLOBE NEWSWIRE) -- Biz2X and Dubai International Financial Centre ( DIFC ) today announced that Frontiers of Digital Finance (FDF) will be an official event at the 2024 Dubai FinTech Summit.
  • FDF Dubai will feature key industry leaders from financial institutions, technology platforms, global consultancies, and government officials in an invite-only event on May 8, 2024.
  • In collaboration with DIFC Innovation Hub, the event will also spotlight Dubai's groundbreaking Vision D33 for transforming finance in the Emirates.
  • We are proud to be hosting these urgent and powerful conversations with the Frontiers of Digital Finance series."

Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks

Retrieved on: 
Tuesday, March 12, 2024

Appili’s Director of Non-Clinical Research, Dr. Carl Gelhaus, Ph.D., together with medical doctors from the United States Uniformed Services University of the Health Sciences and Ukrainian researchers published a perspective manuscript “ Considerations for prevention of and emergency response to tularemia outbreaks in Ukraine: vaccine involvement ”.

Key Points: 
  • Appili’s Director of Non-Clinical Research, Dr. Carl Gelhaus, Ph.D., together with medical doctors from the United States Uniformed Services University of the Health Sciences and Ukrainian researchers published a perspective manuscript “ Considerations for prevention of and emergency response to tularemia outbreaks in Ukraine: vaccine involvement ”.
  • “Appili has been developing ATI-1701 , a biodefense vaccine, to protect warfighters from tularemia.” said Carl Gelhaus, Ph.D., Director of Non-Clinical Research of Appili Therapeutics.
  • “With the help of our Ukrainian colleagues and U.S. Army physicians, we have assessed the potential risk for tularemia outbreaks in Ukraine, by reviewing the literature of previous wartime outbreaks in Eastern Europe.
  • Many of the conditions for tularemia outbreaks now exist in Ukraine, and their warfighters need protection.

Paul Martino, Co-Founder of VillageMD, Joins Parsley Health as Chair of the Board

Retrieved on: 
Wednesday, April 3, 2024

Parsley Health , a digital health company designed to improve health status and lower costs in patients with complex and chronic conditions using root cause medicine, today announced that accomplished healthcare executive, Paul Martino, has been appointed as Chair of the Board.

Key Points: 
  • Parsley Health , a digital health company designed to improve health status and lower costs in patients with complex and chronic conditions using root cause medicine, today announced that accomplished healthcare executive, Paul Martino, has been appointed as Chair of the Board.
  • "Parsley Health simplifies complex health care, manages costs and ultimately helps patients live healthier lives,” said Paul Martino.
  • His leadership and partnership will be instrumental in accelerating Parsley’s growth,” said Dr. Robin Berzin, M.D., Founder, and CEO of Parsley Health.
  • Founded in 2016 by Dr. Robin Berzin, MD, a Columbia-trained physician and digital health expert, Parsley Health originally opened with brick-and-mortar centers in New York and California.

CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

Retrieved on: 
Tuesday, March 19, 2024

They also underscore that a therapeutic vaccine that can rebalance the inflammatory disease process, promoting antigen-specific disease-directed T cell immune responses, is highly desirable.

Key Points: 
  • They also underscore that a therapeutic vaccine that can rebalance the inflammatory disease process, promoting antigen-specific disease-directed T cell immune responses, is highly desirable.
  • “At CEL-SCI, we focus on utilizing a healthy immune system to overcome disease safely and with minimal side effects.
  • Our LEAPS platform, and CEL-4000 specifically approaches the treatment of auto immune diseases like rheumatoid arthritis in a completely different way.
  • “The growing body of preclinical data on LEAPS supports the advancement of this asset into human studies.”

Sonde Health's Voice-Based Mental Fitness Solution Accurately Identifies Individuals with Elevated Mental Health Symptoms

Retrieved on: 
Monday, March 11, 2024

A new study from Sonde Health has validated the company's mental fitness vocal biomarker (MFVB) platform ’s ability to reliably distinguish individuals with elevated mental health symptoms.

Key Points: 
  • A new study from Sonde Health has validated the company's mental fitness vocal biomarker (MFVB) platform ’s ability to reliably distinguish individuals with elevated mental health symptoms.
  • The four-week cohort study revealed a statistically significant correlation between voice-based identification of increased or decreased mental health risk with the results of the M3 Checklist, a clinically validated mental health assessment.
  • Those who used it 5-6 times per week were 8.5 times more likely to demonstrate elevated mental health symptoms via the M3 Checklist.
  • We believe the MFVB can foster stronger awareness about individuals’ mental well-being, thereby encouraging them to cultivate healthy habits and proactively mitigate their mental health risks."

Research case series presents food as medicine as a potential treatment for lupus and other autoimmune diseases

Retrieved on: 
Tuesday, March 19, 2024

ST. LOUIS, March 19, 2024 /PRNewswire-PRWeb/ -- A new research case series published in Frontiers in Nutrition presents food as medicine as a potential treatment for autoimmune diseases, describing three patients with chronic autoimmune disease who showed remarkable improvement after following a predominantly raw dietary pattern high in cruciferous vegetables and omega 3 fatty acids.

Key Points: 
  • ST. LOUIS, March 19, 2024 /PRNewswire-PRWeb/ -- A new research case series published in Frontiers in Nutrition presents food as medicine as a potential treatment for autoimmune diseases, describing three patients with chronic autoimmune disease who showed remarkable improvement after following a predominantly raw dietary pattern high in cruciferous vegetables and omega 3 fatty acids.
  • All three women reported that nearly all their symptoms of both diseases resolved after just four weeks of making the dietary changes.
  • "My hope is that these cases generate greater recognition, making patients and clinicians aware of food as medicine as a treatment option for systemic lupus erythematosus and Sjögren's syndrome.
  • This case series also reflects the immediate need for more research into dietary changes as a potential treatment strategy for autoimmune disease."

China’s universities just grabbed 8 of the top 10 spots in one worldwide science ranking – without changing a thing

Retrieved on: 
Wednesday, April 3, 2024

Rankings influence student matriculation numbers, attract talented faculty and justify donations from wealthy donors.

Key Points: 
  • Rankings influence student matriculation numbers, attract talented faculty and justify donations from wealthy donors.
  • University leaders rail against them, and some schools “withdraw” from them, but rankings are influential.
  • A radical shift in the data underlying rankings is about to upend the rankings world – largely in favor of China’s position.
  • China’s swift progress in science and technology, propelled by investments in research and university strength, has alarmed the United States and other nations.

Broader range of more sources

  • But careful curation makes it the gold standard of academic indexing and one that journals and authors aspire to join.
  • Reliance on curated databases is about to end with the introduction of rankings based on open data like that collected by OpenAlex.
  • OpenAlex claims to include over 100,000 journals – of highly varying quality and editorial practices – compared with SCI’s 9,200.

Reflecting China’s research productivity

  • As China has invested in education and grown its science and engineering capacity, many more people turn out scholarly articles.
  • From a very small number in the 1980s, China had 2.2 million scientists and engineers by 2023, based on UNESCO data.
  • China’s scholarly output of scientific and engineering articles shows a very rapid rise since the 1990s, with growth outpacing all other nations.
  • Open-access publishing services have grown rapidly and offer fast publication times, but there are questions about the quality of their journals.
  • Chinese researchers and their sponsoring institutions put a huge premium on publishing in international journals, even those hosted by questionable publishers.


Caroline Wagner does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Retrieved on: 
Thursday, February 22, 2024

BOTHELL, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2023, and reviewed recent pipeline and business updates.

Key Points: 
  • In December 2023, the Company announced encouraging results from the exploratory Phase 2 SHAPE clinical trial to evaluate fosgonimeton in patients with Parkinson's disease dementia and dementia with Lewy bodies.
  • In May 2023, Athira selected the 40 mg dose for further development and potential regulatory approval.
  • In January 2024, Athira completed enrollment of the LIFT-AD study, randomizing approximately 315 patients in the primary analysis population.
  • In December 2023, Athira announced encouraging results from the exploratory SHAPE Phase 2 clinical trial of fosgonimeton for the potential treatment of Parkinson's disease dementia and dementia with Lewy bodies.

Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

Retrieved on: 
Tuesday, February 20, 2024

Sudocetaxel zendusortide is an investigational, first-in-class peptide-drug conjugate (PDC) that targets the sortilin receptor (SORT1) and expedites the internalization and delivery of the cytotoxic payload (docetaxel) directly into cancer cells.

Key Points: 
  • Sudocetaxel zendusortide is an investigational, first-in-class peptide-drug conjugate (PDC) that targets the sortilin receptor (SORT1) and expedites the internalization and delivery of the cytotoxic payload (docetaxel) directly into cancer cells.
  • The article, “Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing” appears in the “Cancer Immunity and Immunotherapy” section of the February (Volume 15) issue of the journal.
  • Additionally, combining sudocetaxel zendusortide with an anti-PD-L1 checkpoint inhibitor led to increases in tumor growth inhibition and median animal survival.
  • This realization supports the rationale for further exploration of the combination of sudocetaxel zendusortide with immunotherapy.”